Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, CHDI Expand Research Pact | Contract Pharma
Breaking News, Collaborations & Alliances

Evotec, CHDI Expand Research Pact

Extends Huntington’s collaboration through 2015

The CHDI Foundation, Inc. (CHDI), a privately-funded research organization, has extended its collaboration with Evotec AG through 2015. Evotec will provide medicinal chemistry, in vitro and in vivo pharmacology, and compound management. The contract has a potential value of $41 million in research payments for Evotec.

“We are delighted that CHDI, an organization dedicated solely to the quest to discover novel drugs against Huntington’s disease, continues to work in partnership with Evotec,” said Dr. Mario Polywka, chief operating officer of Evotec. “This collaboration is an excellent example of how companies, including foundations such as CHDI, can access Evotec’s platform suite of technologies, capabilities and strong disease biology expertise, to drive their drug discovery efforts.”

“CHDI partners with a global network of investigators from the academic, biopharmaceutical, and service sectors to execute our drug discovery and development efforts,” said Dr. Robert Pacifici, chief scientific officer at CHDI. “Evotec represents one of our largest and longest standing relationships with a contract research organization. We are delighted that, with the renewal of our contract, CHDI and Evotec will be able to continue our productive interactions and drive our therapeutic programs forward.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters